Irina Pivneva
Affiliations: | McGill University, Montreal, QC, Canada |
Area:
Bilingualism; Executive controlGoogle:
"Irina Pivneva"Mean distance: 106866
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Titone D, Mercier J, Sudarshan A, et al. (2020) Spoken word processing in bilingual older adults: Assessing within- and cross-language competition using the visual world task Linguistic Approaches to Bilingualism |
| Ritchie EK, Latremouille-Viau D, Guerin A, et al. (2019) Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective. Leukemia & Lymphoma. 1-9 |
| Lin F, Kwong J, Ionescu-Ittu R, et al. (2019) Work productivity loss in patients with tenosynovial giant cell tumors in the United States. Journal of Clinical Oncology. 37: e22527-e22527 |
| Dana R, Bradley JL, Guerin A, et al. (2018) Comorbidities and Prescribed Medications in Patients With or Without Dry Eye Disease: A Population-Based Study. American Journal of Ophthalmology |
| Seiter K, Latremouille-Viau D, Guerin A, et al. (2018) Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States. Advances in Therapy |
| Borghaei H, Yim YM, Guerin A, et al. (2018) Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy. Lung Cancer (Amsterdam, Netherlands). 119: 112-119 |
| Lin F, Ionescu-Ittu R, Pivneva I, et al. (2018) Disability burden in patients with tenosynovial giant cell tumors in the United States from employer perspective. Journal of Clinical Oncology. 36: 92-92 |
| Ritchie EK, Sadek I, Pivneva I, et al. (2018) Symptoms following TKI therapy discontinuation after achieving an adequate response in patients with chronic myeloid leukemia in chronic phase (CML-CP). Journal of Clinical Oncology. 36 |
| Seiter K, Latremouille-Viau D, Guerin A, et al. (2018) Comparison of Healthcare Resource Utilization (HRU) and Costs Related to Pleural Effusion (PE) Between Patients Newly Diagnosed with Chronic Myeloid Leukemia (CML) Treated with Dasatinib or Nilotinib as First-Line Therapy in the United States Value in Health. 21 |
| Ritchie EK, Sadek I, Pivneva I, et al. (2018) Symptoms Following Discontinuation of Tyrosine Kinase Inhibitor (TKI) Therapy After Achieving an Adequate Response in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Clinical Lymphoma, Myeloma & Leukemia. 18 |